Journal
JOURNAL OF PARKINSONS DISEASE
Volume 8, Issue 1, Pages 33-43Publisher
IOS PRESS
DOI: 10.3233/JPD-171285
Keywords
Glycation; Maillard-reaction; Parkinson's disease; alpha-synuclein
Categories
Funding
- Fundacao para a Ciencia e Tecnologia (FCT), Portugal [SFRH/BPD/109347/2015, PTDC/NEU-OSD/5644/2014]
- DFG Center for Nanoscale Microscopy of the Brain (CNMPB)
- EU Joint Programme - Neurodegenerative Disease Research (JPND) project (aSynProtec)
- JPND (BMBF)
Ask authors/readers for more resources
Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available